Researchers 3-D print lifelike artificial organ models

A team of researchers led by the University of Minnesota has 3D printed lifelike artificial organ models that mimic the exact anatomical structure, mechanical properties, and look and feel of real organs. These patient-specific organ models, which include integrated soft sensors, can be used for practice surgeries to improve surgical outcomes in thousands of patients worldwide.

The research was published today in the journal Advanced Materials Technologies. The researchers are submitting a patent on this technology.

"We are developing next-generation organ models for pre-operative practice. The organ models we are 3D printing are almost a perfect replica in terms of the look and feel of an individual's organ, using our custom-built 3D printers," said lead researcher Michael McAlpine, an associate professor of mechanical engineering in the University of Minnesota's College of Science and Engineering and a 2017 recipient of the Presidential Early Career Award for Scientists and Engineers (PECASE).

"We think these organ models could be 'game-changers' for helping surgeons better plan and practice for surgery. We hope this will save lives by reducing medical errors during surgery," McAlpine added.

McAlpine said his team was originally contacted by Dr. Robert Sweet, a urologist at the University of Washington who previously worked at the University of Minnesota. Sweet was looking for more accurate 3D printed models of the prostate to practice surgeries.

Currently, most 3D printed organ models are made using hard plastics or rubbers. This limits their application for accurate prediction and replication of the organ's physical behavior during surgery. There are significant differences in the way these organs look and feel compared to their biological counterparts. They can be too hard to cut or suture. They also lack an ability to provide quantitative feedback.

In this study, the research team took MRI scans and tissue samples from three patients' prostates. Researchers tested the tissue and developed customized silicone-based inks that can be "tuned" to precisely match the mechanical properties of each patient's prostate tissue. These unique inks were used in a custom-built 3D printer by researchers at the University of Minnesota. The researchers then attached soft, 3D printed sensors to the organ models and observed the reaction of the model prostates during compression tests and the application of various surgical tools.

"The sensors could give surgeons real-time feedback on how much force they can use during surgery without damaging the tissue," said Kaiyan Qiu, a University of Minnesota mechanical engineering postdoctoral researcher and lead author of the paper. "This could change how surgeons think about personalized medicine and pre-operative practice."

In the future, researchers hope to use this new method to 3D print lifelike models of more complicated organs, using multiple inks. For instance, if the organ has a tumor or deformity, the surgeons would be able to see that in a patient-specific model and test various strategies for removing tumors or correcting complications. They also hope to someday explore applications beyond surgical practice.

"If we could replicate the function of these tissues and organs, we might someday even be able to create 'bionic organs' for transplants," McAlpine said. "I call this the 'Human X' project. It sounds a bit like science fiction, but if these synthetic organs look, feel, and act like real tissue or organs, we don't see why we couldn't 3D print them on demand to replace real organs."

Kaiyan Qiu, Zichen Zhao, Ghazaleh Haghiashtiani, Shuang-Zhuang Guo, Mingyu He, Ruitao Su, Zhijie Zhu, Didarul B Bhuiyan, Paari Murugan, Fanben Meng, Sung Hyun Park, Chih-Chang Chu, Brenda M Ogle, Daniel A Saltzman, Badrinath R Konety, Robert M Sweet, Michael C McAlpine.
3D Printed Organ Models with Physical Properties of Tissue and Integrated Sensors.
Adv. Mater. Technol. 2365-709X. doi: 10.1002/admt.201700235.

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

For first time in 40 years, cure for acute leukemi…

Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemi...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...

Tezepelumab granted Breakthrough Therapy Designati…

AstraZeneca and its partner Amgen Inc. (Amgen) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab...

Pfizer terminates domagrozumab (PF-06252616) clini…

Pfizer Inc. (NYSE: PFE) announced that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrop...

Pfizer and Astellas amend clinical research protoc…

Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced amendments to the protocols for two registratio...